AstraZeneca Plc (AZN)

53.87
1.10 2.10
NYSE : Health Technology
Prev Close 55.00
Open 54.59
Day Low/High 53.76 / 55.27
52 Wk Low/High 36.15 / 57.44
Volume 4.44M
Avg Volume 5.23M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 140.76B
EPS 0.50
P/E Ratio 24.54
Div & Yield 1.37 (2.48%)
AstraZeneca Provides Cautious 2017 Guidance

AstraZeneca Provides Cautious 2017 Guidance

AstraZeneca posted stronger-than-expected earnings in the fourth quarter but was hesitant about 2017.

News Out of Europe: Reckitt Benckiser Confirms $16.7 Billion Mead Johnson Approach

News Out of Europe: Reckitt Benckiser Confirms $16.7 Billion Mead Johnson Approach

Here is a round-up of the headlines from Europe.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices

Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices

Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.

AstraZeneca upgraded at Leerink

AstraZeneca Reports Positive Lung Cancer Drug Trial Results

AstraZeneca Reports Positive Lung Cancer Drug Trial Results

AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.

What to Watch This Week: Presidential Election, Mylan Earnings

What to Watch This Week: Presidential Election, Mylan Earnings

For the week of November 7, all eyes will be on Tuesday's presidential election.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer

Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer

Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.

Cempra Is Ready to Run

Cempra Is Ready to Run

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.

Big Pharma Has No Rx for Viral Social Media Reactions

Big Pharma Has No Rx for Viral Social Media Reactions

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer is making another acquisition.

4 Stocks to Avoid Amid the Mad 'Search for Yield'

4 Stocks to Avoid Amid the Mad 'Search for Yield'

There's a price to pay for low expectations.

Closing Bell: Tinder Boosts Match; Earnings Drive S&P 500 Higher

Closing Bell: Tinder Boosts Match; Earnings Drive S&P 500 Higher

Another busy day on the earnings calendar kept trading erratic again on Thursday, though the S&P 500 and Nasdaq managed to clinch slight gains by the end of the session.

AstraZeneca Likely to Grind Lower

AstraZeneca Likely to Grind Lower

Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.

Bret Jensen Reporting for Duty

Good morning! Bret Jensen here! It's good to be standing in for Doug Kass on Doug's Daily Dairy this Friday, especially on a day when my "Best Idea" Relypsa (RLYP) is likely to soar. After the bell Thursday, the U.S. Food and Drug Administration ess...

2 Small-Cap Biotechs With Big Ambitions

2 Small-Cap Biotechs With Big Ambitions

Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.

Relypsa's Still a Bargain Despite 67% Rally

Relypsa's Still a Bargain Despite 67% Rally

Small biotech has plenty of cash and a very valuable drug.

Relypsa's Still a Bargain Despite 67% Rally

Relypsa's Still a Bargain Despite 67% Rally

Small biotech has plenty of cash and a very valuable drug.

Tax Clampdown Prompts Pfizer to Scrap Allergan Purchase

CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.

Revisiting 3 Promising Small Biotechs

Revisiting 3 Promising Small Biotechs

They are oversold and lately been on the move.

Don't Throw This Biotech 'Baby' Out With the Bathwater

Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.

Don't Throw This Biotech 'Baby' Out With the Bathwater

Don't Throw This Biotech 'Baby' Out With the Bathwater

Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.

Biotech Stocks Are Beginning to Stir

Biotech Stocks Are Beginning to Stir

I am starting to get more confident that the small caps are ready to bounce.

AstraZeneca downgraded at Jefferies

AstraZeneca's Ailment Doesn't Look Treatable

AstraZeneca's Ailment Doesn't Look Treatable

AZN looks vulnerable to further declines. The next downside support area and price target are the $26-$24 area. 

2 Speculative Biotech Stocks for 2016

2 Speculative Biotech Stocks for 2016

Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.